Regado Biosciences Downgraded to “Hold” at Deutsche Bank (RGDO)
Regado Biosciences (NASDAQ:RGDO) was downgraded by analysts at Deutsche Bank from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, TheFlyOnTheWall.com reports. They currently have a $2.00 price objective on the stock, down from their previous price objective of $14.00. Deutsche Bank’s price target would indicate a potential downside of 29.58% from the stock’s previous close.
Regado Biosciences (NASDAQ:RGDO) opened at 2.84 on Monday. Regado Biosciences has a 52-week low of $2.22 and a 52-week high of $14.10. The stock has a 50-day moving average of $2.73 and a 200-day moving average of $6.31. The company’s market cap is $95.4 million.
Regado Biosciences (NASDAQ:RGDO) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.63) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.51) by $0.12. Analysts expect that Regado Biosciences will post $-2.20 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on RGDO. Analysts at Cowen and Company downgraded shares of Regado Biosciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 13th. Separately, analysts at Needham & Company LLC downgraded shares of Regado Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, July 7th. They now have a $13.00 price target on the stock. Finally, analysts at BMO Capital Markets downgraded shares of Regado Biosciences from an “outperform” rating to an “underperform” rating in a research note on Thursday, July 3rd. They now have a $1.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $7.67.
Regado Biosciences, Inc is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.